Wolverine 10mg BPC-157 5mg + TB-500 5mg Research Blend Australia
Wolverine 10mg is a fixed-ratio research blend containing BPC-157 5mg and TB-500 5mg in one vial, for 10mg total nominal peptide content. The informal terms Wolverine Blend and Wolverine Stack are widely used in the research-peptide market for the BPC-157 + TB-500 pairing.
This Australian Peptide listing specifically identifies a single premixed vial. That distinction matters because some products marketed as a “Wolverine stack” are two separate vials rather than one co-formulated research blend.
Looking to buy a BPC-157 + TB-500 Wolverine blend in Australia for laboratory research? This 10mg presentation is supplied from Australia strictly for lawful laboratory, analytical and in-vitro research. It is not intended for human, veterinary, therapeutic, cosmetic or personal use.
Key Features
- BPC-157 5mg + TB-500 5mg
- 10mg total nominal peptide content
- Fixed 1:1 blend by labelled mass
- Single premixed lyophilised vial
- Strength-specific product and batch record
- Batch-specific Janoshik COA required before sale
- Australian dispatch
Product Specifications
Product Name: Wolverine 10mg Research Peptide Blend
BPC-157: 5mg nominal content
TB-500: 5mg nominal content
Total Nominal Content: 10mg
Nominal Ratio: 1:1
Format: Single premixed vial
Physical Form: Lyophilised powder
Research Category: Dual-peptide research blend
Country of Dispatch: Australia
BPC-157 Research Context
BPC-157 is a synthetic 15-amino-acid peptide investigated predominantly in preclinical models. Published laboratory and animal research has examined peptide signalling, nitric-oxide-related pathways, angiogenesis-associated processes and connective-tissue models.
The evidence boundary matters. A 2026 scientific review noted that despite decades of preclinical work, BPC-157 remains pharmaceutically underdeveloped, with no approved formulation, no validated dosing regimen and no completed Phase II clinical trial. Findings from experimental models should therefore not be presented as established human outcomes.
Read the full Australian Peptide overview: Understanding BPC-157 in Modern Biochemistry Literature.
TB-500 Research Context and Identity
TB-500 is a research-market name associated with thymosin beta-4-related peptide material. Thymosin beta-4 literature has examined actin binding, cytoskeletal organisation, endothelial-cell migration and angiogenesis. However, commercial TB-500 nomenclature is not a substitute for analytical identity.
This is particularly important because published analytical work has identified shorter thymosin beta-4-related fragments in products sold under the TB-500 name. The exact identity of the material supplied should therefore be established through the batch-specific analytical record rather than assumed from the catalogue name alone.
Read our detailed guide: Understanding TB-500 in Modern Biochemistry Literature.
For the combined formulation, see What Is the Wolverine Blend? BPC-157 + TB-500 Research Guide.
What the Wolverine Name Does — and Does Not — Mean
“Wolverine” is an informal catalogue nickname for the BPC-157 + TB-500 pairing. It is not the name of one chemical entity, one amino-acid sequence or one clinically validated treatment. This blend contains two distinct research materials with separate analytical identities.
Research on BPC-157 alone, thymosin beta-4-related materials alone or separate-vial combinations does not automatically establish the safety, efficacy or behaviour of this exact 5mg + 5mg co-formulated preparation.
Certificate of Analysis and Batch Verification
Australian Peptide requires a batch-specific Janoshik Certificate of Analysis for the active sale batch. For a two-component blend, the documentation should meaningfully address the identity and composition of the actual BPC-157 + TB-500 material being supplied rather than relying on a generic certificate from another product or batch.
Researchers should match the batch identifier on the vial with the applicable record in the COA Library. Learn more through Quality Assurance, Certificate of Analysis Explained and Research Peptide Quality Standards.
10mg vs 20mg Wolverine Blend
The 10mg and 20mg Australian Peptide Wolverine presentations use the same nominal 1:1 BPC-157 : TB-500 ratio. The difference is total labelled mass: this 10mg listing contains 5mg + 5mg, while the Wolverine 20mg Research Blend contains 10mg + 10mg.
The higher-strength listing is not a different peptide identity; it is a larger nominal quantity of the same two-component formulation.
Related Research Products
Researchers who need independent control of the two materials can review BPC-157 10mg and TB-500 10mg as separate products. This may be preferable for experimental designs where component ratios need to be varied rather than fixed at 1:1.
For general mass and concentration terminology, see What Does mg Mean on a Peptide Vial?.
Frequently Asked Questions
What is Wolverine 10mg?
It is a single research vial containing 5mg nominal BPC-157 and 5mg nominal TB-500, for 10mg total labelled content.
Is this one vial or two?
One vial. This listing is a premixed BPC-157 + TB-500 blend, not two separately packaged vials.
Why is it called the Wolverine Stack?
“Wolverine Stack” is informal research-market shorthand for the BPC-157 + TB-500 pairing. The nickname does not represent a clinical indication or therapeutic claim.
Does the blend have one CAS number or one molecular weight?
No. It is a mixture of two distinct research materials, so the individual components retain their own analytical identities.
Where can laboratories buy Wolverine 10mg in Australia?
Australian Peptide supplies this 5mg + 5mg research blend online in Australia for lawful laboratory and analytical research, with Australian dispatch and batch-specific documentation required for the active sale batch.
Is this product intended for human use?
No. It is supplied strictly for laboratory, analytical and in-vitro research, with no dosing, administration or therapeutic guidance provided.
Australian Peptide Research Standards
Australian Peptide supplies research materials with an emphasis on clear product identification, batch traceability and accessible analytical documentation. Active peptide batches are required to have batch-specific documentation that matches the material being supplied.
- Australian dispatch
- Batch-specific analytical documentation
- Janoshik Certificate of Analysis required for the active sale batch
- COA Library access and batch traceability
- Research-focused product information
- Price Match Guarantee for eligible comparable Australian listings
Current retail promotions, multi-vial savings, complimentary-vial eligibility and shipping offers are applied according to the terms displayed on the website and at checkout.
